Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 3
2010 1
2011 7
2012 4
2013 8
2014 5
2015 14
2016 8
2017 11
2018 11
2019 12
2020 11
2021 7
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 34410972

92 results
Results by year
Filters applied: . Clear all
Page 1
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K. Fujita Y, et al. Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13. Oncologist. 2019. PMID: 30425180 Free PMC article. Clinical Trial.
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL. Rasmussen MH, et al. Mol Oncol. 2013 Jun;7(3):637-46. doi: 10.1016/j.molonc.2013.02.016. Epub 2013 Feb 28. Mol Oncol. 2013. PMID: 23506979 Free PMC article.
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Hurwitz HI, et al. Oncologist. 2019 Jul;24(7):921-932. doi: 10.1634/theoncologist.2018-0344. Epub 2018 Dec 14. Oncologist. 2019. PMID: 30552157 Free PMC article. Clinical Trial.
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
Laurent-Puig P, Grisoni ML, Heinemann V, Liebaert F, Neureiter D, Jung A, Montestruc F, Gaston-Mathe Y, Thiébaut R, Stintzing S. Laurent-Puig P, et al. Clin Cancer Res. 2019 Jan 1;25(1):134-141. doi: 10.1158/1078-0432.CCR-18-1324. Epub 2018 Aug 14. Clin Cancer Res. 2019. PMID: 30108104 Free article. Clinical Trial.
Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P. Manceau G, et al. Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25. Clin Cancer Res. 2014. PMID: 24771647 Free article.
92 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page